Roche lends weight to Swiss biotech; Regeneron makes genomic headway;

@FierceBiotech: Astellas backs out of a $760M Alzheimer's deal with CoMentis. Item | Follow @FierceBiotech

@JohnCFierce: This low-T field is definitely starting to look like the slum area of R&D. | Follow @JohnCFierce

@DamianFierce: Early look at Adaptimmune's cancer immunotherapy data: 1 complete response and 3 partials among 5 patients. Story | Follow @DamianFierce

@EmilyMFierce:  The

> Roche ($RHHBY) is teaming up with Swiss biotech Cardiorentis, lending diagnostic know-how as the company works through a Phase III trial of an acute heart failure treatment. More

> Pharmacyclics ($PCYC) has signed a deal with to study its Johnson & Johnson ($JNJ)-partnered cancer treatment in tandem with Roche's ($RHHBY) Gazyva. News

> Regeneron ($REGN) is moving forward with its wholly owned genetics lab, sequencing about 10,000 genomes and striking collaboration with Columbia University, Baylor and others. Release

Medical Device News

@FierceMedDev: Medical device venture deals pull in more money per deal. More | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Invitae raises $120M to offer cheap, easy genetic analysis. Story | Follow @VarunSaxena2

@EmilyWFierce: Stryker scores with Q3 earnings, beating the Street's expectations and posting $2.39B in revenue. Article | Follow @EmilyWFierce

@MichaelGFierce: Stealthy, DNA-based 'nano-cocoons' deliver #cancer-killing payloads. News | Follow @MichaelGFierce

> Former GE Healthcare head John Dineen joins private equity group. More

> Stryker to repatriate $2B, ready for acquisitions in 2H15. Story

> Boston Scientific wins CE mark for MRI-friendly pacemaker products. News

Pharma News

@FiercePharma: Tops in FierceVaccines Thurs: NewLink Ebola vaccine trial begins in U.S. while Glaxo takes its jab to Mali. Story | Follow @FiercePharma

@EricPFierce: I suspect Laura Schumacher spent late nights as AbbVie board decided whether to walk away from Shire deal. Report | Follow @EricPFierce

@CarlyHFierce: ICYMI: This week's issue of FierceVaccines. Subscribe here to get it weekly. Subscribe | Follow @CarlyHFierce

> Lilly will close Puerto Rico plant affecting 100 workers. Article

> FDA says Pfizer's Chantix must continue to wear a 'black box' label. Story

> AbbVie's $1.635B breakup fee to Shire, if paid, will run third highest ever. Item

Suggested Articles

Panelists at the CAR-TCR Summit reflected on gender diversity trends and the challenges women face in the life sciences industry.

Loh joins the computational chemistry specialist after a two-year stint at Kymera Therapeutics.

The $3 billion funding boost includes an additional $350 million for targeted Alzheimer’s research.